Climb Bio (NASDAQ:CLYM) Rating Increased to Strong-Buy at BTIG Research

Climb Bio (NASDAQ:CLYM) was upgraded by stock analysts at BTIG Research to a “strong-buy” rating in a research report issued on Thursday, Marketbeat reports. The firm presently has a $7.00 price target on the stock. BTIG Research’s price objective would suggest a potential upside of 483.33% from the company’s previous close.

Climb Bio Stock Down 0.8%

Shares of CLYM opened at $1.20 on Thursday. The stock has a market cap of $81.09 million, a PE ratio of -0.56 and a beta of -0.12. The firm’s fifty day moving average price is $1.25. Climb Bio has a twelve month low of $1.05 and a twelve month high of $9.58.

Climb Bio (NASDAQ:CLYM) last announced its quarterly earnings results on Wednesday, May 14th. The company reported ($0.31) earnings per share for the quarter, missing the consensus estimate of ($0.15) by ($0.16). On average, analysts predict that Climb Bio will post -1.57 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of CLYM. Bank of New York Mellon Corp bought a new position in shares of Climb Bio in the 1st quarter worth about $79,000. Peapod Lane Capital LLC bought a new position in shares of Climb Bio in the 1st quarter worth about $676,000. TD Asset Management Inc bought a new position in shares of Climb Bio in the 1st quarter worth about $109,000. XTX Topco Ltd bought a new position in shares of Climb Bio in the 1st quarter worth about $34,000. Finally, Charles Schwab Investment Management Inc. bought a new position in shares of Climb Bio in the 1st quarter worth about $86,000. 69.76% of the stock is currently owned by institutional investors.

Climb Bio Company Profile

Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company’s lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases.